Anetumab in Thymic Carcinoma

Anetumab 在胸腺癌中的应用

• 批准号: 10702743
• 负责人: Arun Rajan
• 金额: $ 1.99万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10702743
• 关键词: Adverse event; Antibody-drug conjugates; Clinical Trials; Cornea; Development; Disease; Enrollment; In complete remission; Interruption; Multicenter Trials; Patients; Peripheral Nervous System Diseases; Thymic Carcinoma; base; efficacy evaluation; experience; mesothelin; neoplastic cell; objective response rate; preclinical study

This multicenter trial is evaluating the mesothelin-targeting antibody-drug conjugate, anetumab ravtansine in subjects with thymic carcinoma. This clinical trial is based on a preclinical study conducted by our group that showed strong, membranous expression of mesothelin in thymic carcinoma. Three patients have been enrolled and treated with anetumab. One patient experienced a durable complete response and two patients had durable stabilization of disease. Adverse events associated with anetumab were manageable and included peripheral neuropathy and development of corneal microcysts, which are reversible with interruption of treatment.

这项多中心试验正在评估胸腺癌受试者中靶向靶性抗体抗体 - 药物缀合物，anetumab ravtansine。该临床试验是基于我们组进行的一项临床前研究，该研究表明，在胸腺癌中，间皮素的膜状表达强。三名患者已入学并接受了苯珠单抗治疗。 一名患者经历了持久的完全反应，两名患者对疾病的稳定稳定。与臂行相关的不良事件是易于管理的，包括周围神经病和角膜微囊囊的发育，它们在治疗中断时可逆。